INTELLIA THERAPEUTICS, INC. (NTLA) Operating Margin
- Operating margin · 12 months: Value -711.66%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -711.66% | Operating income / revenue. Period ending 2026-06-30. $-423.48M ÷ $59.51M × 100 ≈ -711.66% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -423.48M USD | Operating Income (Loss) |
| Revenue | 59.51M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 346.73M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-423.48M | $59.51M | (m) | $346.73M | (m) | -711.66% |
| 2026-03-31 | $-420.71M | $66.09M | (m) | $361.17M | (m) | -636.56% |
| 2025-12-31 | $-440.99M | $67.67M | (m) | $388.86M | (m) | -651.67% |
| 2025-09-30 | $-478.73M | $57.53M | (m) | $417.09M | (m) | -832.16% |
| 2025-06-30 | $-512.02M | $52.86M | (m) | $445.72M | (m) | -968.69% |
| 2025-03-31 | $-541.07M | $45.57M | (m) | $462.89M | (m) | -1187.36% |
| 2024-12-31 | $-534.26M | $57.88M | (m) | $466.31M | (m) | -923.10% |
| 2024-09-30 | $-537.71M | $43.09M | (m) | $458.42M | (m) | -1247.99% |
| 2024-06-30 | $-524.04M | $45.97M | (m) | $448.73M | (m) | -1140.05% |
| 2024-03-31 | $-517.34M | $52.60M | (m) | $449.80M | (m) | -983.45% |
| 2023-12-31 | $-515.29M | $36.27M | (m) | $435.07M | (m) | -1420.51% |
| 2023-09-30 | $-485.49M | $51.77M | (m) | $426.12M | (m) | -937.87% |
| 2023-06-30 | $-459.91M | $53.04M | (m) | $409.08M | (m) | -867.11% |
| 2023-03-31 | $-425.88M | $53.48M | (m) | $384.00M | (m) | -796.40% |
| 2022-12-31 | $-458.16M | $52.12M | (m) | $419.98M | (m) | -879.04% |
| 2022-09-30 | $-428.49M | $51.40M | (m) | $391.11M | (m) | -833.61% |
| 2022-06-30 | $-394.95M | $45.34M | (m) | $354.94M | (m) | -871.10% |
| 2022-03-31 | $-365.67M | $37.86M | (m) | $323.63M | (m) | -965.85% |
| 2021-12-31 | $-267.85M | $33.05M | $0.00 | $229.81M | (m) | -810.37% |
| 2021-09-30 | $-229.83M | $26.79M | (m) | $196.88M | (m) | -857.78% |
| 2021-06-30 | $-185.94M | $41.81M | (m) | $176.15M | (m) | -444.73% |
| 2021-03-31 | $-149.96M | $51.52M | (m) | $155.03M | (m) | -291.05% |
| 2020-12-31 | $-136.58M | $57.99M | $0.00 | $150.41M | (m) | -235.51% |
| 2020-09-30 | $-123.95M | $62.34M | (m) | $143.91M | (m) | -198.85% |
| 2020-06-30 | $-121.18M | $50.73M | (m) | $131.66M | (m) | -238.87% |
| 2020-03-31 | $-115.61M | $45.59M | (m) | $119.35M | (m) | -253.60% |
| 2019-12-31 | $-106.37M | $43.10M | $0.00 | $108.41M | (m) | -246.78% |
| 2019-09-30 | $-97.34M | $40.05M | $0.00 | $96.60M | (m) | -243.07% |
| 2019-06-30 | $-96.11M | $36.84M | $0.00 | $92.32M | (m) | -260.90% |
| 2019-03-31 | $-92.25M | $33.40M | (m) | $90.33M | (m) | -276.21% |
| 2018-12-31 | $-90.87M | $30.43M | $0.00 | $89.11M | (m) | -298.58% |
| 2018-09-30 | $-94.84M | (m) | (m) | $90.37M | (m) | (m) |
| 2018-06-30 | $-86.61M | (m) | (m) | $84.61M | (m) | (m) |
| 2018-03-31 | $-79.04M | (m) | (m) | $76.71M | (m) | (m) |
| 2017-12-31 | $-69.56M | (m) | (m) | $67.65M | (m) | (m) |
| 2017-09-30 | $-55.66M | (m) | (m) | $57.81M | (m) | (m) |
| 2017-06-30 | $-47.48M | (m) | (m) | $48.19M | (m) | (m) |
| 2017-03-31 | $-38.41M | (m) | (m) | $40.05M | (m) | (m) |
| 2016-12-31 | $-32.16M | (m) | (m) | $31.84M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-13.41M | (m) | (m) | $11.17M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |